Institut Pasteur Shanghai creates global biotech accelerator Advance BioChina

30 March 2011

The not-for-profit Institut Pasteur of Shanghai has announced the creation of its global biotech accelerator company Advance BioChina, which will provide access to funding and full incubation services paying special attention to secure the intellectual property of its joint venture partners.

Advance BioChina is an R&D-focused for-profit organization that positions itself as the gateway to China for global biotech companies. It co-invests with global biotech companies into Shanghai-based JVs. Advance BioChina will incubate and develop up to 25 companies over the next five years to help them develop innovative products for the Chinese and global markets.

Advance BioChina's founder Institut Pasteur of Shanghai (IPS) was established by the Chinese Academy of Sciences, Institut Pasteur and the Shanghai Municipal Government in 2004 and is a legally independent non-profit research organization.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK